title: LV-powered coronary sinus retroperfusion reduces infarct size in acutely ischemic pigs.
abstract: BACKGROUND
  We developed a prosthetic left ventricle (LV) to coronary sinus (CS) shunt (LVCSS) that is autoregulating and provides LV-powered retrograde perfusion of the coronary sinus.
  
  
  METHODS
  Each of 20 Yorkshire pigs underwent 1 hour of left anterior descending diagonal artery occlusion followed by 3 hours of reperfusion. The controls (n = 5) did not have shunt treatment. The LVCSS group (n = 9) underwent shunt treatment during the ischemic period. The LVCSS with partial coronary sinus occlusion (PCSO) group (LVCSS+PCSO, n = 6) underwent shunt treatment and PCSO during the ischemic period. Vital staining and planimetry techniques were used to determine the area at risk for infarction and the area of necrosis.
  
  
  RESULTS
  The area at risk was not significantly different among groups. The area of necrosis was decreased by 53% in the LVCSS group and by 73% in the LVCSS+PCSO group when compared to controls (p<0.01 among all groups).
  
  
  CONCLUSIONS
  The LVCSS reduces infarct size in pigs after acute coronary artery occlusion. The addition of PCSO to LVCSS further improves myocardial salvage.
authors.affiliation: Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: J S
authors.initials: JS
authors.lastname: Martin
authors.forename: J G
authors.initials: JG
authors.lastname: Byrne
authors.forename: O Y
authors.initials: OY
authors.lastname: Ghez
authors.forename: U
authors.initials: U
authors.lastname: Sayeed-Shah
authors.forename: S D
authors.initials: SD
authors.lastname: Grachev
authors.forename: R G
authors.initials: RG
authors.lastname: Laurence
authors.forename: L H
authors.initials: LH
authors.lastname: Cohn
mesh_terms: D000818:Animals; D001243:Assisted Circulation / Q000295:instrumentation / Q000379:methods*; D001794:Blood Pressure / Q000502:physiology; D002302:Cardiac Output / Q000502:physiology; D004396:Coloring Agents; D003326:Coronary Circulation / Q000502:physiology; D003327:Coronary Disease / Q000150:complications; D003331:Coronary Vessels; D006339:Heart Rate / Q000502:physiology; D006352:Heart Ventricles; D006353:Heart-Assist Devices; D009203:Myocardial Infarction / Q000473:pathology / Q000628:therapy*; D017202:Myocardial Ischemia / Q000473:pathology / Q000628:therapy*; D015425:Myocardial Reperfusion / Q000295:instrumentation / Q000379:methods*; D009336:Necrosis; D012307:Risk Factors; D013552:Swine; D014022:Tissue Survival; D016277:Ventricular Function, Left / Q000502:physiology; D017725:Ventricular Pressure / Q000502:physiology
chemical_list: D004396:Coloring Agents